FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, has commenced the first patient enrollment in the AGILITY study to evaluate the safety and efficacy of its Vascular Covered Stent for Peripheral Arterial Disease (PAD) treatment. The study, which is part of an investigational device exemption (IDE), will involve 315 patients across the United States, Europe, Australia, and New Zealand.
The Vascular Covered Stent, a self-expanding nitinol implant encased in polytetrafluoroethylene, is designed to conform to the vessel wall and provide durability. "We're excited to see how this technology performs," stated Dr. Sean Lyden, the study's National Principal Investigator.
PAD, affecting over 18 million Americans and 236 million people globally, can lead to severe cardiovascular issues and limb amputation. Lifestyle changes and minimally invasive procedures are current interventions for PAD, which is characterized by atherosclerosis and blood clots in leg arteries.
Tim Hug, vice president and general manager at BD Peripheral Intervention, expressed optimism about the study's potential to address unmet needs in PAD treatments and enhance their product offerings. The first enrollment took place at Trinity Medical Center, Bettendorf, Iowa, by Dr. Nicolas Shammas.
BD, a prominent medical technology company, is known for its contributions to medical discovery, diagnostics, and care delivery. Employing over 70,000 people, BD aims to improve healthcare safety and efficiency worldwide.
This press release statement serves as the source for the above information.
InvestingPro Insights
As BD (Becton, Dickinson and Company) (NYSE: BDX) embarks on a pivotal study for its Vascular Covered Stent, investors and stakeholders may look at the company's financial health and market performance to gauge its potential for future growth and innovation. According to InvestingPro Data, BD's market capitalization stands at a robust $67.98 billion, reflecting the company's significant presence in the healthcare equipment and supplies industry.
From a valuation perspective, BD is currently trading at a price-to-earnings (P/E) ratio of 55.48, which suggests a high earnings multiple compared to some of its peers. However, when looking at the adjusted P/E ratio for the last twelve months as of Q1 2024, the figure is more favorable at 35.51, indicating potential investor confidence in the company's earnings capacity going forward.
InvestingPro Tips highlight that BD has raised its dividend for 53 consecutive years and is expected to see net income growth this year. These factors, combined with a dividend yield of 1.61% and a history of maintaining dividend payments for 54 consecutive years, may appeal to income-focused investors seeking stability in their portfolio.
Furthermore, as BD trades near its 52-week low with a price percentage of 81.9% of its 52-week high, it could potentially signal a buying opportunity for value investors, especially considering that analysts predict the company will be profitable this year. For those interested in exploring additional insights, there are over 10 InvestingPro Tips available, which can be accessed with a subscription. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.